WO1999012531A3 - Mittel zur hormonalen kontrazeption - Google Patents

Mittel zur hormonalen kontrazeption Download PDF

Info

Publication number
WO1999012531A3
WO1999012531A3 PCT/DE1998/002636 DE9802636W WO9912531A3 WO 1999012531 A3 WO1999012531 A3 WO 1999012531A3 DE 9802636 W DE9802636 W DE 9802636W WO 9912531 A3 WO9912531 A3 WO 9912531A3
Authority
WO
WIPO (PCT)
Prior art keywords
contraceptive
hormonal
hormonal contraceptive
gestagen
oestrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1998/002636
Other languages
English (en)
French (fr)
Other versions
WO1999012531A2 (de
Inventor
Rolf-Dieter Hesch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7842000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999012531(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to EP98954135A priority Critical patent/EP1011682B1/de
Priority to AU11409/99A priority patent/AU1140999A/en
Priority to US09/508,648 priority patent/US6500814B1/en
Priority to DE59808545T priority patent/DE59808545D1/de
Priority to AT98954135T priority patent/ATE241361T1/de
Priority to DK98954135T priority patent/DK1011682T3/da
Publication of WO1999012531A2 publication Critical patent/WO1999012531A2/de
Publication of WO1999012531A3 publication Critical patent/WO1999012531A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die Erfindung betrifft ein Mittel zur hormonalen Kontrazeption mit zwei Hormonkomponenten, wobei das Mittel eine erste Hormonkomponente, die mindestens ein Gestagen umfaßt, und eine zweite Hormonkomponente, die mindestens ein Estrogen umfaßt, zur kontinuierlichen und kombinierten Verabreichung umfaßt. Das erfindungsgemäße Mittel gewährleistet eine hohe kontrazeptive Sicherheit und zuverlässige Unterdrückung des Menstruationszyklus.
PCT/DE1998/002636 1997-09-11 1998-09-03 Mittel zur hormonalen kontrazeption Ceased WO1999012531A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP98954135A EP1011682B1 (de) 1997-09-11 1998-09-03 Mittel zur hormonalen kontrazeption
AU11409/99A AU1140999A (en) 1997-09-11 1998-09-03 Hormonal contraceptive
US09/508,648 US6500814B1 (en) 1997-09-11 1998-09-03 Hormonal contraceptive
DE59808545T DE59808545D1 (de) 1997-09-11 1998-09-03 Mittel zur hormonalen kontrazeption
AT98954135T ATE241361T1 (de) 1997-09-11 1998-09-03 Mittel zur hormonalen kontrazeption
DK98954135T DK1011682T3 (da) 1997-09-11 1998-09-03 Hormonalt antikonceptionsmiddel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19739916A DE19739916C2 (de) 1997-09-11 1997-09-11 Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE19739916.9 1997-09-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/508,648 A-371-Of-International US6500814B1 (en) 1997-09-11 1998-09-03 Hormonal contraceptive
US10/299,628 Continuation US20030073673A1 (en) 1997-09-11 2002-11-19 Hormonal contraceptive product

Publications (2)

Publication Number Publication Date
WO1999012531A2 WO1999012531A2 (de) 1999-03-18
WO1999012531A3 true WO1999012531A3 (de) 1999-09-23

Family

ID=7842000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/002636 Ceased WO1999012531A2 (de) 1997-09-11 1998-09-03 Mittel zur hormonalen kontrazeption

Country Status (9)

Country Link
US (4) US6500814B1 (de)
EP (4) EP1935423A3 (de)
AT (1) ATE241361T1 (de)
AU (1) AU1140999A (de)
DE (2) DE19739916C2 (de)
DK (1) DK1011682T3 (de)
ES (1) ES2200384T3 (de)
PT (1) PT1011682E (de)
WO (1) WO1999012531A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030355A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
FR2754179B1 (fr) * 1996-10-08 1998-12-24 Theramex Nouvelle composition hormononale et son utilisation
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
AU2002338277B2 (en) * 2001-03-16 2007-11-22 Wyeth Estrogen replacement therapy
DE60217324T2 (de) * 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
US7732430B2 (en) * 2001-05-23 2010-06-08 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
EP1390041B1 (de) * 2001-05-23 2009-11-25 Pantarhei Bioscience B.V. Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
ATE347365T1 (de) * 2001-11-15 2006-12-15 Pantarhei Bioscience Bv Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie
MXPA04005445A (es) * 2001-12-05 2005-03-23 Barr Lab Inc Anticonceptivos orales para prevenir el embarazo y disminuir la sintomatologia premenstrual.
CA2489270C (en) * 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
AU2003274946A1 (en) * 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
US9034854B2 (en) 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ATE409041T1 (de) * 2003-03-28 2008-10-15 Pantarhei Bioscience Bv Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind
JP2006525358A (ja) * 2003-05-02 2006-11-09 ドゥラメド ファーマシューティカルズ， インコーポレイテッド 長期周期避妊養生法を利用するホルモン治療の方法
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
JP2007507534A (ja) * 2003-10-01 2007-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 持続的三相避妊方法
EP1522306A1 (de) * 2003-10-08 2005-04-13 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Ein pharmazeutisches Produkt zur Hormonersatztherapie enthaltend Tibolon oder eines seiner Derivate und Oestradiol oder eines seiner Derivate
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
WO2006013464A1 (en) * 2004-07-27 2006-02-09 Amistad Pharma Sas Hormone replacement therapy comprising a combination of 17-beta-oestradiol and chlormadinone acetate
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
WO2006036055A2 (en) * 2004-09-27 2006-04-06 Pantarhei Bioscience B. V. Method of female contraception and kit for use in such method
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
ES2558030T3 (es) * 2006-03-02 2016-02-01 Warner Chilcott Company, Llc Método anticonceptivo oral multifásico de ciclo prolongado
CN101583363B (zh) * 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒
DE102007011486A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
HUE027463T2 (en) 2008-05-28 2016-09-28 Reveragen Biopharma Inc Non-hormonal steroid modulators of nf-kb for treatment of disease
EP2343963B1 (de) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermale freisetzung
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010054061A1 (en) * 2008-11-10 2010-05-14 Wms Gaming Inc. Gaming system having system wide tournament features
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CA2986039A1 (en) * 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
ES3005883T3 (en) 2015-06-22 2025-03-17 Lipocine Inc 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN105030792B (zh) * 2015-06-30 2017-08-25 上海交通大学 Desogestrel在制备抗结肠癌/ER阴性的Ah受体阳性的乳腺癌产品中的应用
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309263A2 (de) * 1987-09-24 1989-03-29 Jencap Research Limited Hormon-Zusammensetzung und -Anwendung
EP0628312A1 (de) * 1993-03-12 1994-12-14 JENAPHARM GmbH Kombinationspräparat zur Kontrazeption

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
FR2589735A1 (fr) * 1985-11-07 1987-05-15 Beillon Xavier Compositions anticonceptionnelles contenant un oestrogene et un progestatif
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
JP3238389B2 (ja) * 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
DE3916381A1 (de) * 1989-05-17 1990-11-22 Schering Ag Verwendung von gestoden zur herstellung von arzneimitteln
DE4019670A1 (de) * 1990-06-22 1992-01-09 Erhard Dr Med Roemer Arzneimittel zur behandlung der wechseljahre der frau
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4405591C1 (de) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
WO1996008255A1 (en) * 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Transdermal device for delivery of levonorgestrel
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309263A2 (de) * 1987-09-24 1989-03-29 Jencap Research Limited Hormon-Zusammensetzung und -Anwendung
EP0628312A1 (de) * 1993-03-12 1994-12-14 JENAPHARM GmbH Kombinationspräparat zur Kontrazeption

Also Published As

Publication number Publication date
ATE241361T1 (de) 2003-06-15
US20030073673A1 (en) 2003-04-17
EP1011682A2 (de) 2000-06-28
EP1310257A3 (de) 2003-07-16
EP1310257A2 (de) 2003-05-14
AU1140999A (en) 1999-03-29
EP1011682B1 (de) 2003-05-28
US20040243606A1 (en) 2004-12-02
DE19739916A1 (de) 1999-03-18
EP1319404A2 (de) 2003-06-18
PT1011682E (pt) 2003-10-31
DE59808545D1 (de) 2003-07-03
WO1999012531A2 (de) 1999-03-18
EP1319404A3 (de) 2003-07-09
ES2200384T3 (es) 2004-03-01
DK1011682T3 (da) 2003-09-22
US20050004088A1 (en) 2005-01-06
EP1935423A3 (de) 2010-01-06
EP1935423A2 (de) 2008-06-25
DE19739916C2 (de) 2001-09-13
US6500814B1 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
EP1310257A3 (de) Kombination zur hormonalen Kontrazeption
WO1997023228A3 (de) Verfahren und kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen
HUP9900252A2 (hu) Hormonális fogamzásgátló, kombinációs kit készítmény
ZA200007299B (en) Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol.
SI0770388T1 (en) Multiphase contraceptive preparation based on natural estrogens
HUS1200002I1 (hu) Egy ösztrogén vegyületet és egy progesztatív vegyületet tartalmazó hormonkészítmény
NO845194L (no) Flertrinnskombinasjonspreparat og anvendelse av dette som oralt antikonsepsjonsmiddel
IL115399A0 (en) A pharmaceutical composition comprising a combination of prostacyclin with an estrogen or progestin
WO2002009719A1 (en) Antitumor agents
DE69710896D1 (en) Progestogen-anti-progestogen therapien
PL334518A1 (en) Derivatives of 16-hydroxy-11-(phenyl-substituted) -estra-4,9-diene-
AU4604796A (en) Orthopaedic brace having one-piece cuff
AU2001248849A1 (en) Estra-1,3,5(10)-triene derivatives
WO1997006807A3 (de) Kombinationspräparat zur kontrazeption, kits diese enthaltend und eine methode diese verwendend
EP1090639A3 (de) Pharmazeutische Zusammensetzung enthaltend einen progestationäle Kortikoid und einen selektiven Östrogenrezeptormodulator
Dori et al. Cilioretinal artery occlusion: an ocular complication of primary antiphospholipid syndrome.
MXPA02002043A (es) Composicion farmaceutica de etinilestradiol y drospirenona para el uso como anticonceptivo.
WO1999025360A3 (en) Progestogen-antiprogestogen regimens
MXPA02004083A (es) Nuevo medicamento contraceptivo y su modo de preparacion.
WO2002055086A3 (en) Hormone replacement therapy method and its administration form
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
AU1092095A (en) Intra-uterine ring for the release of an active agent, such as a hormone, and an introducer
WO1996028154A3 (de) Verwendung von antiestrogenen zur männlichen fertilitätskontrolle
AR010296A1 (es) Uso de una combinacion de una progestina y un estrogeno y un equipo anticonceptivo para administracion oral
IL120398A0 (en) Low dosage contraceptive

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998954135

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09508648

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998954135

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1998954135

Country of ref document: EP